Table 4.
Lifetime cost (USD) of each dialysis modality strategy as first-line treatment and incremental cost-effectiveness ratio in base-case scenario
| Perspective | Strategy | Cost (USD) | Incremental Cost (USD) | Effectiveness (QALY) | Incremental Effectiveness | ICER (USD / QALY gained) |
|---|---|---|---|---|---|---|
| Healthcare provider | ||||||
| PDa | 76,915 | NA | 7.13 | NA | NA | |
| Home-based HD | 97,917 | 21,002 | 8.37 | 1.24 | 16,934 | |
| Hospital-based HD | 142,389 | 44,472 | 6.58 | Dominated by PD | ||
| Societal | ||||||
| PDa | 109,668 | NA | 7.13 | NA | NA | |
| Home-based HD | 111,150 | 1482 | 8.37 | 1.24 | 1195 | |
| Hospital-based HD | 166,648 | 56,980 | 6.58 | Dominated by PD | ||
NA Not applicable, QALY quality-adjusted life-year, ICER incremental cost-effectiveness ratio
aPD is the reference category when calculating incremental cost and incremental effectiveness